HSS Journal

, Volume 5, Issue 2, pp 159–160 | Cite as

Is There a Role for NFAT Inhibitors in the Prevention of Bone Destruction?

  • Mark S. McMahon
Review Article


Pathologic conditions resulting from excessive bone destruction include osteoporosis, rheumatoid arthritis, metastases, periprosthetic osteolysis, cherubism, and others. A scarcity of molecular targets in bone has thwarted the development of drugs to combat these conditions. Nuclear factor of activated T-cells (NFAT) is a master regulator of osteoclastogenesis and is induced by RANKL. The immunosuppressive drugs, Cyclosporin A and Tacrolimus, inhibit osteoclast formation by targeting the NFAT/calcineurin pathway. These NFAT inhibitors should be considered in the treatment of osteoclastic hyper-resorptive syndromes.


osteoclast NFAT Cyclosporin A Tacrolimus calcineurin 


  1. 1.
    Day CJ, Kim MS, Lopez CM et al (2005) NFAT expression in human osteoclasts. J. Cell Biochem 95(1):17–23PubMedCrossRefGoogle Scholar
  2. 2.
    Lietman SA, Yin L, Levine MA (2008) SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem. Biophys. Res. Commun 371(4):644–648PubMedCrossRefGoogle Scholar
  3. 3.
    Clipstone NA, Crabtree GR (1992) Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357(6380):695–697PubMedCrossRefGoogle Scholar
  4. 4.
    Beals CR, Clipstone NA, Ho SN et al (1997) Nuclear localization of NFATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev 11(7):824–834PubMedCrossRefGoogle Scholar
  5. 5.
    Takayanagi H, Kim S, Koga T et al (2002) Induction and activation of the transcription factor NFATc1(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3:889–901PubMedCrossRefGoogle Scholar
  6. 6.
    Hirotani H, Tuohy NA, Woo JT et al (2004) The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J. Biol. Chem 279(14):13984–13992PubMedCrossRefGoogle Scholar
  7. 7.
    Asagiri M, Sato K, Usami T et al (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med 202:1261–1269PubMedCrossRefGoogle Scholar
  8. 8.
    Ishida N, Hayashi K, Hoshijima M et al (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J. Biol. Chem 277(43):41147–41156PubMedCrossRefGoogle Scholar
  9. 9.
    Komarova SV, Pereverzev A, Shum JW et al (2005) Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc. Natl. Acad. Sci. U S A 102(7):2643–2648PubMedCrossRefGoogle Scholar
  10. 10.
    Yeo H, Beck LH, Thompson SR et al (2007) Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J. Biol. Chem 282(48):35318–35327PubMedCrossRefGoogle Scholar
  11. 11.
    Sun L, Peng Y, Zaidi N et al (2007) Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am. J. Physiol. Renal Physiol 292(1):F285–F291PubMedCrossRefGoogle Scholar
  12. 12.
    Kino T, Hatanaka H, Hashimoto M et al (1987) FK-506, a novel immunosuppressant isolated from a streptomyces. 1. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) 40(9):1249–1255Google Scholar
  13. 13.
    Miyazaki M, Fujikawa Y, Takita C et al (2007) Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun orMITF in rheumatoid arthritis. Clin. Rheumatol 26(2):231–239PubMedCrossRefGoogle Scholar
  14. 14.
    Timmerman LA, Clipstone NA, Ho SN et al (1996) Rapid shuttling of NFAT in discrimination of Ca2+ signals and immunosuppression. Nature 383:837–840PubMedCrossRefGoogle Scholar
  15. 15.
    Day CJ, Kim MS, Stephens SRJ et al (2004) Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J. Cell Biochem 91:303–315PubMedCrossRefGoogle Scholar
  16. 16.
    Epstein S, Shane E, Bilezikian JP (1995) Organ transplantation and osteoporosis. Curr. Opin. Rheumatol 7(3):255–261PubMedCrossRefGoogle Scholar
  17. 17.
    Yamanaka Y, Abu-Amer W, Foglia D et al (2008) NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis. J. Orthop. Res 26(12):1577–1584PubMedCrossRefGoogle Scholar

Copyright information

© Hospital for Special Surgery 2009

Authors and Affiliations

  1. 1.Department of Orthopedic SurgeryBeth Israel Deaconess Medical CenterBostonUSA
  2. 2.Department of Developmental BiologyHarvard SDMBostonUSA

Personalised recommendations